Adam, his BFF Shkreli, and by association Herper from Forbes, will never say anything positive about this company, its founder, or its drug until its sales support what the bulls believe. See below for my prognostication of the events to occur, and their response:

Action: Mannkind Releases Spectacular Data From Affinity 1 and 2

Reaction: The trials were rigged, titration of fasting glucose is not "real world", it doesn't matter if the results were great, Exubera failed and thus doctors won't prescribe it, and a partner won't touch it.

Action: Mannkind partners with big pharma company for marketing of Afrezza and application of their drug(s) to the Technosphere platform

Reaction: Big pharma company is stupid and throwing millions of dollars away that could be invested on a drug that cures diabetes, and is now the laughing stock of the world, see what my expert David Kliff has written

Action: Afrezza gets approved with a requirement for inexpensive spirometry for all type 1s, and Type II's who are failing metformin, and not smokers or have COPD

Reaction: Providers don't want nor need an ultra rapid acting insulin and sales will be dismal, ultimately resulting in it being pulled just like Exhubera, just wait!

Action: Mannkind cannot keep up with the demand for Afrezza and its profit margin due to a minisucle COGS, is off the charts.

Reaction: I WAS WRONG, IF YOU'LL EXCUSE ME I'LL FIND ANOTHER COMPANY TO TRASH